Lucy Scientific Discovery IncNASDAQ:LSDINASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.8192
- TODAY'S CHANGE (%)0.0122 (1.5118%)
- Bid / Lots0.7900/ 20
- Ask / Lots0.8699/ 1
- Open / Previous Close0.8062 / 0.8070
- Day Range
- 52 Week Range
- Volume18,491
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LSDI |
|---|---|---|
| 10:21 ET | 2000 | 0.8062 |
| 10:26 ET | 231 | 0.82 |
| 10:30 ET | 2481 | 0.8062 |
| 11:13 ET | 242 | 0.822 |
| 11:27 ET | 1900 | 0.822 |
| 11:36 ET | 1849 | 0.84115 |
| 12:00 ET | 719 | 0.822 |
| 12:38 ET | 900 | 0.8 |
| 01:10 ET | 2404 | 0.8 |
| 01:53 ET | 555 | 0.85 |
| 02:00 ET | 500 | 0.8699 |
| 02:42 ET | 323 | 0.8 |
| 03:12 ET | 152 | 0.84 |
| 03:36 ET | 1976 | 0.8192 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Lucy Scientific Discovery Inc | 1.4M | -0.1x | --- |
Vestiage Inc | 1.2M | -25.3x | --- |
Link Reservations Inc | 1.6M | 0.0x | --- |
Neutra Corp | 1.2M | -2.2x | --- |
Nunzia Pharmaceutical Corp | 1.3M | 0.0x | --- |
Nexien Biopharma Inc | 1.1M | -3.9x | --- |
Company Information
Lucy Scientific Discovery Inc. is an early stage psychotropics contract manufacturing company. The Company is engaged in researching, developing, and manufacturing psychotropic drugs. The Company is a manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies. It is focused on developing therapies for patients in need, and through its lead candidate SANA-013, dedicated to advancing the understanding and applications of psychedelic medicine, improving mental health outcomes, and enhancing well-being for individuals worldwide. The Company is engaged in the production of a variety of natural, synthetic, and biosynthetic products to meet the needs of the psychotropics-based medicines market. Its products are in the form of raw materials, crude extracts, targeted formulations, single molecule fractions, and white- and private-label products.
Contact Information
- Headquarters
- 301-1321 Blanshard StreetVICTORIA, BC, Canada V8W 0B6
- Phone
- 778-410-5195
- Fax
- ---
Executives
- Executive Chairman of the Board, Chief Executive Officer
- Richard Nanula
- Chief Financial Officer
- Brian Zasitko
- Chief Scientific Officer
- Assad Kazeminy
- Independent Director
- Paul Abramowitz
- Independent Director
- Brittany Kaiser
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4M |
|---|---|
Revenue (TTM) | $16.7K |
Shares Outstanding | 1.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-6.34 |
Book Value | $2.68 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 86.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -47,783.98% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
